{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:18Z","timestamp":1787595738090,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u251c\u00f1t Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11523-020-00748-4","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T09:02:58Z","timestamp":1602493378000},"page":"599-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":false,"given":"Dietger","family":"Niederwieser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"748_CR1","unstructured":"Rituxan\u00ae (rituximab) prescribing information. Genentech Inc.; 2019."},{"key":"748_CR2","unstructured":"MabThera. Summary of product characteristics. Grenzach-Wyhlen, Germany: Roche Pharma AG; 2019."},{"key":"748_CR3","unstructured":"US Food and Drug Administration. Guidance for industry\u2014questions and answers on biosimilar development and the BPCI Act (revision 1). 2018. https:\/\/www.fda.gov\/media\/119258\/download. Accessed May 11, 2020."},{"key":"748_CR4","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 11 May 2020."},{"key":"748_CR5","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https:\/\/www.fda.gov\/media\/82647\/download. Accessed May 11, 2020."},{"key":"748_CR6","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015. https:\/\/www.fda.gov\/media\/135612\/download. Accessed May 11, 2020."},{"key":"748_CR7","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for industry. 2016. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM397017.pdf. Accessed May 11, 2020."},{"key":"748_CR8","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies\u2014non-clinical and clinical issues. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 11 May 2020."},{"key":"748_CR9","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). 2014.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf. Accessed May 11, 2020."},{"key":"748_CR10","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products (revision 1). 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed May 11, 2020."},{"key":"748_CR11","doi-asserted-by":"publisher","unstructured":"Seo N, Huang A, Kuhns S, Sweet H, Cao S, Wikstr\u00f6m M, Liu J. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. Biologicals. 2020. https:\/\/doi.org\/10.1016\/j.biologicals.2020.08.002.","DOI":"10.1016\/j.biologicals.2020.08.002"},{"issue":"1","key":"748_CR12","first-page":"5001","volume":"130","author":"H McBride","year":"2017","unstructured":"McBride H, Maher G, Sweet H, Foltz I, Kuhns S. Functional similarity of proposed biosimilar ABP 798 with rituximab. Blood. 2017;130(1):5001.","journal-title":"Blood"},{"key":"748_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.845","author":"G Burmester","year":"2020","unstructured":"Burmester G, Chien D, Chow V, Gessner M, Pan J, Cohen S. A randomized, double-blind study comparing pharmacokinetics and pharmacodynamics of proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate to severe rheumatoid arthritis. Clin Pharmacol Drug Dev. 2020. https:\/\/doi.org\/10.1002\/cpdd.845.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"748_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424\u201335.","journal-title":"Lancet Oncol"},{"key":"748_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3322\/canjclin.55.6.368","volume":"55","author":"JO Armitage","year":"2005","unstructured":"Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55:368\u201376.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"748_CR16","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-C\u00e9ligny","year":"1998","unstructured":"Solal-C\u00e9ligny P, Lepage E, Brousse N, Tendler CL, Brice P, Ha\u00efoun C, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des lymphomes folliculaires 86 trial. J Clin Oncol. 1998;16(7):2332\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"748_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkins lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.","journal-title":"J Clin Oncol."},{"key":"748_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood.V116.21.6.6","volume":"116","author":"K Ardeshna","year":"2010","unstructured":"Ardeshna K, Qian W, Smith P, Warden J, Stevens L, Pocock CFE, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood. 2010;116:6.","journal-title":"Blood"},{"issue":"8","key":"748_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803\u201343.","journal-title":"Drugs"},{"key":"748_CR20","unstructured":"American Cancer Society. Cancer Facts and Figures 2020. Atlanta: American Cancer Society; 2020. Available at https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf. Accessed August 17, 2020."},{"issue":"1","key":"748_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/annonc\/mdh002","volume":"15","author":"SA Pileri","year":"2004","unstructured":"Pileri SA, Zinzani PL, Went P, Pileri A Jr, Bendandi M. Indolent lymphoma: the pathologist's viewpoint. Ann Oncol. 2004;15(1):12\u20138.","journal-title":"Ann Oncol"},{"issue":"9383","key":"748_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(03)14110-4.","journal-title":"Lancet"},{"issue":"15","key":"748_CR23","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986\u201392. https:\/\/doi.org\/10.1200\/JCO.2006.06.4618.","journal-title":"J Clin Oncol"},{"issue":"1","key":"748_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/ijh.12.7","volume":"1","author":"Q Chen","year":"2012","unstructured":"Chen Q, Ayer T, Nastoupil LJ, Seward M, Zhang H, Sinha R, et al. Initial management strategies for follicular lymphoma. Int J Hematol Oncol. 2012;1(1):35\u201345. https:\/\/doi.org\/10.2217\/ijh.12.7.","journal-title":"Int J Hematol Oncol"},{"issue":"2","key":"748_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93(2):296\u2013305. https:\/\/doi.org\/10.1002\/ajh.24937.","journal-title":"Am J Hematol"},{"key":"748_CR26","unstructured":"Truxima\u00ae (rituximab-abbs) prescribing information. CELLTRION, Inc.; 2020."},{"key":"748_CR27","unstructured":"Ruxience\u00ae (rituximab-pvvr) prescribing information. Pfizer, Inc.; 2020."},{"issue":"8","key":"748_CR28","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","volume":"4","author":"WS Kim","year":"2017","unstructured":"Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362\u2013e373373. https:\/\/doi.org\/10.1016\/S2352-3026(17)30120-5.","journal-title":"Lancet Haematol"},{"issue":"8","key":"748_CR29","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","volume":"4","author":"W Jurczak","year":"2017","unstructured":"Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350\u2013e361361. https:\/\/doi.org\/10.1016\/S2352-3026(17)30106-0.","journal-title":"Lancet Haematol"},{"issue":"1","key":"748_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","volume":"13","author":"Y Shi","year":"2020","unstructured":"Shi Y, Song Y, Qin Y, Zhang Q, Han X, Hong X, et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13(1):38. https:\/\/doi.org\/10.1186\/s13045-020-00871-9.","journal-title":"J Hematol Oncol."}],"updated-by":[{"DOI":"10.1007\/s11523-020-00772-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-020-00748-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T12:05:50Z","timestamp":1634040350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-020-00748-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00748-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11523-020-00772-4","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"12 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Page 608, 4 Discussion, right column, second paragraph.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Amgen Inc., Thousand Oaks, CA, USA. Open Access funding provided by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dietger Niederwieser reports personal fees from Cellectis, Daiichi, and Novartis. David Chien, Vladimir Hanes, and Mindy Mo are employees and stockholders of Amgen Inc. Patrick Cobb, Vincent Delwail, Cecily Forsyth, Roman Hajek, Caroline Hamm, and Alessandra Tucci have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) regulations\/guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects provided written informed consent prior to entering the study and before initiation of any study-related procedure (including administration of investigational product).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"There is a plan to share data. This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request, and also related data dictionaries, study protocol, statistical analysis plan, informed consent form, and\/or clinical study report. Data sharing requests relating to data in this manuscript will be considered after the publication date and (1) this product and indication (or other new use) have been granted marketing authorization in both the US and Europe or (2) clinical development discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for these data. Qualified researchers may submit a request containing the research objectives, the Amgen product(s), and Amgen study\/studies in scope, endpoints\/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labeling. A committee of internal advisors reviews requests. If not approved, a Data Sharing Independent Review Panel may arbitrate and make the final decision. Requests that pose a potential conflict of interest or an actual or potential competitive risk may be declined at Amgen\u2019s sole discretion and without further arbitration. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and\/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}}]}}